Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Drugs on the horizon for diabesity.

Literature DB >> 16188170

Drugs on the horizon for diabesity.

Abstract

The coexistence of type 2 diabetes and obesity presents a complex therapeutic challenge. Future combination tablets may include agents to address diabetes and any accompanying cardiovascular risk factors. Injectable agents that improve glycemic control and facilitate weight loss have recently become available: the soluble amylin analogue pramlintide provides an adjunct to insulin therapy in type 1 and type 2 diabetes, and the incretin mimetic exenatide can enhance prandial insulin release in type 2 diabetes. Orally active inhibitors of the incretin-degrading enzyme dipeptidyl peptidase-IV, agonists of peroxisome proliferator-activated receptor (PPAR)-a and PPAR-g ("dual PPARs"), and the CB1 cannabinoid receptor inhibitor rimonabant are advanced in clinical development. Many novel antidiabetic and antiobesity compounds are emerging in preclinical development.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2005 PMID： 16188170 DOI： 10.1007/s11892-005-0093-1

Source DB: PubMed Journal: Curr Diab Rep ISSN： 1534-4827 Impact factor: 4.810

60 in total

Review 1. Animal models of non-insulin-dependent diabetes.

Authors: E Shafrir
Journal: Diabetes Metab Rev Date: 1992-10

2. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.

Authors: Michael A Nauck; Markus M Heimesaat; Kai Behle; Jens J Holst; Markus S Nauck; Robert Ritzel; Michael Hüfner; Wolff H Schmiegel
Journal: J Clin Endocrinol Metab Date: 2002-03 Impact factor: 5.958

3. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.

Authors: H-J Mest; R Mentlein
Journal: Diabetologia Date: 2005-03-16 Impact factor: 10.122

4. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors: Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal: Lancet Date: 2005 Apr 16-22 Impact factor: 79.321

Review 5. Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Authors: Andrew J Krentz; Clifford J Bailey
Journal: Drugs Date: 2005 Impact factor: 9.546

6. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity.

Authors: Yong-Xu Wang; Chih-Hao Lee; Sambath Tiep; Ruth T Yu; Jungyeob Ham; Heonjoong Kang; Ronald M Evans
Journal: Cell Date: 2003-04-18 Impact factor: 41.582

7. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

Authors: Ralph A DeFronzo; Robert E Ratner; Jenny Han; Dennis D Kim; Mark S Fineman; Alain D Baron
Journal: Diabetes Care Date: 2005-05 Impact factor: 19.112

8. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice.

Authors: Y L Liu; I P Connoley; C A Wilson; M J Stock
Journal: Int J Obes (Lond) Date: 2005-02 Impact factor: 5.095

9. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.

Authors: Daniela Cota; Giovanni Marsicano; Matthias Tschöp; Yvonne Grübler; Cornelia Flachskamm; Mirjam Schubert; Dorothee Auer; Alexander Yassouridis; Christa Thöne-Reineke; Sylvia Ortmann; Federica Tomassoni; Cristina Cervino; Enzo Nisoli; Astrid C E Linthorst; Renato Pasquali; Beat Lutz; Günter K Stalla; Uberto Pagotto
Journal: J Clin Invest Date: 2003-08 Impact factor: 14.808

Review 10. Incretins, insulin secretion and Type 2 diabetes mellitus.

Authors: T Vilsbøll; J J Holst
Journal: Diabetologia Date: 2004-02-13 Impact factor: 10.122

9 in total

Review 1. New therapies for diabesity.

Authors: Clifford J Bailey
Journal: Curr Diab Rep Date: 2009-10 Impact factor: 4.810

2. Naphthalenemethyl ester derivative of dihydroxyhydrocinnamic acid, a component of cinnamon, increases glucose disposal by enhancing translocation of glucose transporter 4.

Authors: W Kim; L Y Khil; R Clark; S H Bok; E E Kim; S Lee; H S Jun; J W Yoon
Journal: Diabetologia Date: 2006-08-09 Impact factor: 10.122

9. Ficus carica and Sizigium cumini Regulate Glucose and Lipid Parameters in High-Fat Diet and Streptozocin-Induced Rats.

Authors: El-Shaimaa A Arafa; Waseem Hassan; Ghulam Murtaza; Manal Ali Buabeid
Journal: J Diabetes Res Date: 2020-10-28 Impact factor: 4.011